Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

URGN

UroGen Pharma Ltd

Jan 17 • 04:00PM ET

10.27

Dollar change -0.25
Percentage change -2.38	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT BIIB EXEL IONS FOLD ACAD NBIX VKTX PBYI HALO

| Held by: IWM IWO IBB IZRL VTWO SPDW IWC IWN SBIO ITEQ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.14	Insider Own	13.44%	Shs Outstand	42.19M	Perf Week	0.29%
Market Cap	433.39M	Forward P/E	-	EPS next Y	-2.68	Insider Trans	-0.04%	Shs Float	36.53M	Perf Month	-9.12%
Income	-115.38M	PEG	-	EPS next Q	-0.74	Inst Own	89.32%	Short Float	15.95%	Perf Quarter	-18.49%
Sales	89.36M	P/S	4.85	EPS this Y	11.59%	Inst Trans	-8.85%	Short Ratio	12.97	Perf Half Y	-38.28%
Book/sh	0.60	P/B	16.98	EPS next Y	14.47%	ROA	-46.56%	Short Interest	5.83M	Perf Year	-34.12%
Cash/sh	5.94	P/C	1.73	EPS next 5Y	-	ROE	-	52W Range	9.78 - 20.70	Perf YTD	-3.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.89%	ROI	-78.26%	52W High	-50.39%	Beta	1.09
Dividend TTM	-	Quick Ratio	8.77	Sales past 5Y	16454.91%	Gross Margin	90.27%	52W Low	5.01%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	9.00	EPS Y/Y TTM	25.65%	Oper. Margin	-93.70%	RSI (14)	39.53	Volatility	5.59% 5.48%
Employees	201	Debt/Eq	4.81	Sales Y/Y TTM	15.64%	Profit Margin	-129.11%	Recom	1.29	Target Price	39.93
Option/Short	Yes / Yes	LT Debt/Eq	4.78	EPS Q/Q	18.93%	Payout	-	Rel Volume	0.58	Prev Close	10.52
Sales Surprise	4.13%	EPS Surprise	32.69%	Sales Q/Q	20.87%	Earnings	Nov 06 BMO	Avg Volume	449.47K	Price	10.27
SMA20	-3.66%	SMA50	-10.37%	SMA200	-23.94%	Trades		Volume	262,698	Change	-2.38%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-22-24	Initiated	Guggenheim	Buy	$40
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Jan-15-25 08:00AM	ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 (Business Wire)
Dec-06-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-05-24 03:30PM	Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
03:15PM	UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC (Business Wire)
Dec-02-24 05:44PM	Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade (Zacks)
08:00AM	Loading…
08:00AM	UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs (Business Wire)
Nov-28-24 11:49AM	UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment (Clinical Trials Arena)
Nov-26-24 08:00AM	New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
Nov-07-24 02:16AM	UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-24 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 (Business Wire)
Nov-05-24 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference (Business Wire)
Oct-30-24 08:00AM	UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 (Business Wire) +6.29%
Oct-28-24 08:00AM	ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Oct-16-24 04:47AM	FDA accepts UroGens UGN-102 NDA for bladder cancer treatment (Pharmaceutical Technology)
04:30PM	Loading…
Oct-15-24 04:30PM	UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 (Business Wire)
Oct-09-24 06:18PM	UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -9.31%
08:00AM	UroGen Appoints Chris Degnan as Chief Financial Officer (Business Wire)
Oct-03-24 04:12AM	UroGen begins subject dosing in Phase III bladder cancer drug trial (Clinical Trials Arena)
Oct-02-24 08:00AM	First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Sep-23-24 05:50AM	UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now (Insider Monkey)
03:58AM	UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-16-24 08:00AM	UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 (Business Wire)
Sep-05-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-24 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:00AM	UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-13-24 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights (Business Wire)
Aug-05-24 08:00AM	UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 (Business Wire)
Aug-02-24 09:55AM	Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect? (Zacks)
10:01AM	Loading…
Aug-01-24 10:01AM	Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-17-24 09:55AM	Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High? (Zacks)
Jun-27-24 01:54PM	UroGen Pharma Stock Earns 91 RS Rating (Investor's Business Daily)
Jun-17-24 10:51PM	UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (Business Wire) -7.71%
04:46PM	UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
05:00AM	Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains? (Zacks)
Jun-13-24 04:05PM	UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug (Investor's Business Daily) +37.58% +9.71%
10:45AM	UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Jun-07-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-24 08:00AM	UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 (Business Wire)
Jun-05-24 08:00AM	UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-24 08:00AM	UroGen Pharma Appoints David Lin as New Chief Commercial Officer (Business Wire)
May-22-24 08:00AM	UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit (Business Wire)
May-14-24 08:20AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM	UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
May-05-24 12:20PM	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM	New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-03-24 08:00AM	UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals (Business Wire)
Mar-15-24 10:30AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -17.97%
09:32AM	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges (GuruFocus.com)
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 (Business Wire)
Mar-08-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-04-24 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024 (Business Wire)
Feb-26-24 08:00AM	UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference (Business Wire) +5.09%
Feb-01-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
Jan-24-24 08:00AM	UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 (Business Wire)
Jan-17-24 08:00AM	UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers (Business Wire) +6.27%
Jan-11-24 08:00AM	UroGen Pharma to Participate in the B. Riley Healthcare Conference (Business Wire)
Dec-08-23 04:00PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-15-23 01:50PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials (GuruFocus.com)
08:00AM	UroGen Pharma Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-13-23 08:00AM	UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology (Business Wire)
Nov-07-23 08:00AM	UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire)
Oct-03-23 08:00AM	Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 (Business Wire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-08-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-23 01:40PM	UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why (Zacks)
Aug-17-23 07:00AM	New Treatment for Bladder Cancer Offers This Biotech a Second Chance (The Wall Street Journal) -14.16%
Aug-12-23 09:18AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments (Business Wire)
Aug-08-23 08:00AM	The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-02-23 05:00PM	UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (Business Wire) -6.45%
Aug-01-23 10:05AM	Opportunities Outweigh Risks: Oppenheimer Sees at Least 60% Gains in These 2 Stocks (TipRanks) -6.28%
Jul-31-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-23 01:41PM	Why Shares of UroGen Pharma Jumped Friday (Motley Fool) +26.38%
Jul-27-23 09:55AM	UroGen Announces $120 Million Private Placement of Ordinary Shares (Business Wire) +98.56%
09:50AM	UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials (Business Wire)
Jul-25-23 04:10PM	UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors (Business Wire)
Jul-10-23 08:00AM	Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation (Business Wire) -5.28%
Jul-06-23 08:00AM	UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 (Business Wire) +5.08%
Jun-20-23 08:00AM	Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration (Business Wire)
Jun-09-23 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.33%
Jun-02-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
May-22-23 01:18PM	With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
May-16-23 12:13PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.00%
08:00AM	UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Sep 09 '24	Sale	13.08	859	11,236	145,091	Sep 12 01:54 PM
Smith Jason Drew	General Counsel	Sep 09 '24	Sale	13.08	1,521	19,895	25,226	Sep 12 01:51 PM
Schoenberg Mark	Officer	Sep 09 '24	Proposed Sale	13.23	859	11,365		Sep 10 07:16 AM
Schoenberg Mark	Chief Medical Officer	Jun 10 '24	Sale	13.08	5,153	67,401	144,284	Jun 11 01:15 PM
Schoenberg Mark	Chief Medical Officer	Mar 18 '24	Sale	14.05	12,000	168,600	139,437	Mar 20 04:38 PM
Smith Jason Drew	General Counsel	Jan 31 '24	Sale	15.74	4,993	78,590	18,824	Feb 02 07:12 PM
Schoenberg Mark	Chief Medical Officer	Jan 31 '24	Sale	15.74	3,789	59,639	149,423	Feb 02 07:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your FINVIZ experience